Welcome to our dedicated page for Kalaris Therapeutics SEC filings (Ticker: KLRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kalaris Therapeutics, Inc. (NASDAQ: KLRS) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, drawn in real time from the U.S. Securities and Exchange Commission’s EDGAR system. As a Nasdaq-listed clinical-stage biopharmaceutical company, Kalaris files a range of documents that provide insight into its retinal disease programs, corporate structure, and capital markets activity.
Key filings for KLRS include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business focus on treatments for prevalent retinal diseases, summarize the clinical status of its lead investigational therapy TH103, and present audited and interim financial statements. Form 8-K current reports detail material events such as the completion of the merger that established Kalaris’ current business focus, private placement transactions involving common stock and pre-funded warrants, initial Phase 1a data for TH103 in treatment-naïve neovascular AMD patients, and quarterly financial results.
Investors can also use this page to access proxy materials such as the DEF 14A definitive proxy statement, which explains the company’s governance structure, board composition, equity compensation plans, and the transition from AlloVir, Inc. to Kalaris Therapeutics, Inc. In addition, compensation and appointment details for executives, as well as shareholder meeting information, appear in specific 8-K items and proxy sections.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand clinical development updates, financing terms, and governance changes. Users can review insider and equity-related disclosures, follow the evolution of the TH103 program through successive filings, and track how Kalaris describes its risks and forward-looking statements over time.
Kalaris Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Form 8-K and is incorporated by reference.
This Current Report itself does not include any financial figures or operating metrics; it states that the information in the press release is being furnished and shall not be deemed "filed" under the Exchange Act. The filing was submitted on behalf of the company and is signed by Chief Executive Officer Andrew Oxtoby. Readers must consult Exhibit 99.1 for the detailed results.
Invus Public Equities, L.P. and affiliated entities (Invus Public Equities Advisors LLC, Invus Global Management LLC, Siren LLC and Raymond Debbane) submitted Amendment No. 3 to Schedule 13G for Kalaris Therapeutics, Inc. (KLRS).
The group reports direct ownership of 282,586 common shares (CUSIP 482929106), equal to 1.5 % of the 18,702,418 shares outstanding as of 30 Jun 2025. Each reporting person discloses sole voting and dispositive power; no shared power or additional economic interests are indicated.
Because the stake is now below the 5 % threshold, the filing notes “Ownership of 5 percent or less of a class.” The certification further states the shares were not acquired to influence control of the issuer. No other material agreements, transactions or intentions are disclosed.
Investment takeaway: Invus’ position is relatively small and passively held, suggesting limited near-term impact on KLRS governance or trading dynamics.
Kalaris Therapeutics, Inc. (ticker KLRS) has filed Definitive Additional Proxy Materials (Form DEFA14A) ahead of its virtual Annual Meeting of Stockholders scheduled for August 12, 2025 at 11:30 a.m. ET. The notice outlines two routine proposals:
- Proposal 1: Elect Class II directors Srinivas Akkaraju, M.D., Ph.D. and Andrew Oxtoby to three-year terms expiring at the 2028 meeting.
- Proposal 2: Ratify Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
The Board recommends shareholders vote FOR each director nominee and FOR auditor ratification. Shareholders of record at the close of business on June 25, 2025 are entitled to vote. Materials are available at www.proxydocs.com/KLRS; holders must use their 12-digit control number to access voting tools. Paper or email copies of the proxy may be requested without charge until August 1, 2025. No other substantive matters, financial results, or transactional items are disclosed in this filing.
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has filed a Form 8-K to announce scheduling details for its 2025 Annual Meeting of Stockholders.
The Board of Directors set August 12, 2025 as the meeting date. Because this date is more than 30 days later than the 2024 meeting anniversary, the company has adjusted deadlines for shareholder engagement:
- Rule 14a-8 proposals: Must be received by the Corporate Secretary no later than June 30, 2025 to be considered for inclusion in the proxy statement.
- Director nominations or other business under the company’s By-laws: Notice must also be delivered by June 30, 2025, in line with Section 2(a)(2) of the By-laws, because the meeting date is delayed by more than 60 days from the prior-year anniversary.
The filing contains no financial results, strategic transactions, or operational updates. Further details—such as the exact time, physical or virtual location, and the matters up for vote—will be provided in the forthcoming proxy statement.
The disclosure is routine, ensuring regulatory compliance and giving shareholders clear deadlines to submit proposals or nominations.